Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

ReNeuron will begin clinical trial shortly; upbeat on potential deals

The cell technology group said the first of a group of 110 patients taking part in PICSE III will be enrolled soon
picture of an eye
Eye, eye: The company is in negotiations to out-license technology designed to treat retinal disease

ReNeuron Group PLC (LON:RENE) will tell investors at its annual meeting that a Phase IIb clinical trial of its potentially breakthrough CTX cell treatment for stroke will soon get underway in the US.

The first of a group of 110 patients taking part in PICSE III will be enrolled ‘shortly’.

WATCH: 'All systems go' with ReNeuron Group Plc looking to treat first PISCES III patient shortly

Top-line data from the randomised, placebo-controlled study is expected in early 2020, having been previously penciled in for the end of 2019.

In the update, the company said it expected to sign a definitive licensing agreement for its cell-based retinal technology later this year.

It has received a US$2.5mln exclusivity payment and will get the same again from an unnamed potential partner once the due diligence process is concluded.

Negotiations on other collaborations and out-licensing transactions continue.

“These potential deals, if successfully concluded, will provide strong third-party validation to our technologies and programmes as well as a source of significant non-dilutive funding to the company,” investors at the ReNeuron AGM will hear.

Specialist in cell science 

As mentioned above, ReNeuron is a cell therapy specialist. Its CTX line is being developed for stroke patients, while its hRPC stem cell candidate has been used to treat people with retinitis pigmentosa.

The study has now expanded to target people with less impaired vision and the first read-out from this early-stage trial is expected by the middle of next year.

The group's hRPC cells will also be deployed in the phase II study of sufferers of cone-rod dystrophy, which will run in parallel with a planned phase IIb in retinitis pigmentosa.

Turning to ReNeuron's exosome nanomedicine platform, the group's research team presented positive pre-clinical data on an ExoPr0 therapy, which has the potential to target multiple diseases. The plan is to lodge an initial clinical trial application next year for its use in cancer.

View full RENE profile View Profile

ReNeuron Group Plc Timeline

Related Articles

scientist in lab
September 07 2018
Normally, patients have to wait until regulators have approved a drug before they get access to it, but up to 500 lupus sufferers will receive Lupuzor as part of a Managed Access Programme
1534822132_cadoux.jpg
August 21 2018
The company aims to revolutionise the HPA production process, eschewing the laborious bauxite-sourced method.
Laboratory
June 21 2018
Genedrive has signed sales agreement with Sysmex Corporation for the distribution of the HCV ID to EMEA and Asia Pacific and with Mumbai- based ARKRAY to distribute the kit in India

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use